Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Addiction-Pipeline Review, H1 2015

Addiction-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Addiction-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Addiction-Pipeline Review, H1 2015', provides an overview of the Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Addiction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Addiction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Addiction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Addiction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Addiction Overview 11

Therapeutics Development 12

Pipeline Products for Addiction-Overview 12

Pipeline Products for Addiction-Comparative Analysis 13

Addiction-Therapeutics under Development by Companies 14

Addiction-Therapeutics under Investigation by Universities/Institutes 20

Addiction-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Addiction-Products under Development by Companies 26

Addiction-Products under Investigation by Universities/Institutes 33

Addiction-Companies Involved in Therapeutics Development 35

AbbVie Inc. 35

Acura Pharmaceuticals, Inc. 36

Addex Therapeutics Ltd 37

Adial Pharmaceuticals, LLC 38

Alkermes Plc 39

Aphios Corporation 40

Aradigm Corporation 41

Arena Pharmaceuticals, Inc. 42

Astraea Therapeutics, LLC 43

AstraZeneca PLC 44

Beech Tree Labs, Inc. 45

BioDelivery Sciences International, Inc. 46

Bionex Pharmaceuticals LLC 47

Bioprojet SCR 48

Camurus AB 49

Celtic Pharmaceutical Holdings L.P. 50

Cerecor Inc. 51

Curemark, LLC 52

D&A Pharma SAS 53

Eli Lilly and Company 54

Embera NeuroTherapeutics, Inc. 55

Euthymics Bioscience, Inc. 56

Foresee Pharmaceuticals, LLC 57

FORUM Pharmaceuticals Inc. 58

Gilead Sciences, Inc. 59

GlaxoSmithKline plc 60

Grunenthal GmbH 61

Heptares Therapeutics Ltd. 62

Immunovaccine, Inc. 63

Indivior PLC 64

INSYS Therapeutics, Inc. 65

Invion Limited 66

Johnson & Johnson 67

Kyorin Pharmaceutical Co., Ltd. 68

Lightlake Therapeutics Inc. 69

Lohocla Research Corporation 70

MAKScientific, LLC 71

NAL Pharmaceuticals Ltd. 72

Nanotherapeutics, Inc. 73

Omeros Corporation 74

Pfizer Inc. 75

Relmada Therapeutics, Inc. 76

Rottapharm SpA 77

Royalty Pharma 78

Selecta Biosciences, Inc. 79

SK Biopharmaceuticals Co., Ltd. 80

Sun Pharma Advanced Research Company Ltd. 81

Targacept, Inc. 82

Tekmira Pharmaceuticals Corp. 83

Teva Pharmaceutical Industries Limited 84

Titan Pharmaceuticals, Inc. 85

Tonix Pharmaceuticals Holding Corp. 86

VM Discovery, Inc. 87

Zynerba Pharmaceuticals, Inc. 88

Addiction-Therapeutics Assessment 89

Assessment by Monotherapy Products 89

Assessment by Combination Products 90

Assessment by Target 91

Assessment by Mechanism of Action 94

Assessment by Route of Administration 97

Assessment by Molecule Type 99

Drug Profiles 101

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 101

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 102

(disulfiram + selegiline)-Drug Profile 103

(oxazepam + metyrapone)-Drug Profile 104

(topiramate + ondansetron hydrochloride)-Drug Profile 106

ABT-436-Drug Profile 107

ADX-71441-Drug Profile 108

ADX-88178-Drug Profile 109

AM-6527-Drug Profile 110

amitifadine-Drug Profile 112

Anatabine-Drug Profile 114

Antisense Gene Therapy to Inhibit Aldehyde Dehydrogenase for Alcoholism-Drug Profile 115

arbaclofen placarbil-Drug Profile 116

ARD-1600-Drug Profile 118

ASB-Drug Profile 119

AT-1001-Drug Profile 120

baclofen ER-Drug Profile 121

BP-1.4979-Drug Profile 122

BTL-ng-Drug Profile 123

Buprenorphine Hemiadipate Hydrochloride-Drug Profile 124

buprenorphine hydrochloride-Drug Profile 125

buprenorphine hydrochloride-Drug Profile 126

buprenorphine hydrochloride-Drug Profile 127

buprenorphine hydrochloride depot-Drug Profile 130

buprenorphine hydrochloride ER-Drug Profile 131

buprenorphine hydrochloride SR-Drug Profile 132

cannabidiol-Drug Profile 134

cannabidiol-Drug Profile 135

cannabidiol-Drug Profile 137

carisbamate-Drug Profile 138

CM-1212-Drug Profile 140

CR-5542 Series-Drug Profile 141

CR-5772 Series-Drug Profile 142

dipraglurant IR-Drug Profile 143

dronabinol-Drug Profile 144

Drug for Dependence-Drug Profile 145

Drug to Inhibit Triple Reuptake for Alcohol Dependence-Drug Profile 146

Drugs to Activate HAT for CNS Disorders-Drug Profile 147

Drugs to Inhibit FAAH for CNS Disorders-Drug Profile 148

Drugs to Inhibit Histone Deacetylase for CNS Disorders-Drug Profile 149

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders-Drug Profile 150

encenicline hydrochloride-Drug Profile 151

FP-004-Drug Profile 154

FP-007-Drug Profile 155

GET-73-Drug Profile 156

GS-6637-Drug Profile 157

GSK-598809-Drug Profile 158

ibudilast-Drug Profile 159

JNJ-31020028-Drug Profile 161

JNJ-5234801-Drug Profile 162

lorcaserin hydrochloride-Drug Profile 163

LT-22-Drug Profile 166

LY-2456302-Drug Profile 167

LY-2940094-Drug Profile 168

MAL-Drug Profile 169

methadone IR-Drug Profile 170

methoxycoronaridine-Drug Profile 171

nadolol-Drug Profile 172

naltrexone-Drug Profile 174

naltrexone-Drug Profile 175

NIC7-DT-Drug Profile 176

nicotine-Drug Profile 177

nicotine-Drug Profile 178

Nicotine Vaccine-Drug Profile 179

NOX-B11-Drug Profile 180

odelepran hydrochloride-Drug Profile 181

OMS-405-Drug Profile 182

OMS-527-Drug Profile 183

ondansetron hydrochloride-Drug Profile 185

PF-04457845-Drug Profile 186

PF-05402536-Drug Profile 187

PF-06413367-Drug Profile 188

PF-5006739-Drug Profile 189

phantasmidine-Drug Profile 190

RO-656570-Drug Profile 191

samidorphan-Drug Profile 192

saracatinib difumarate-Drug Profile 193

SEL-068-Drug Profile 195

SLV-330-Drug Profile 197

Small Molecule for Central Nervous System-Drug Profile 198

Small Molecule for Drug Addiction-Drug Profile 200

Small Molecule for Smoking Cessation-Drug Profile 201

Small Molecule for Smoking Cessation and Appetite Suppression-Drug Profile 202

Small Molecule to Activate Kappa Opioid Receptor for CNS-Drug Profile 203

Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 204

Small Molecule to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation-Drug Profile 205

Small Molecule to Antagonize Ghrelin for Alcoholism-Drug Profile 206

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction-Drug Profile 207

Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders-Drug Profile 208

Small Molecule to Inhibit BRD for Cocaine Dependence-Drug Profile 209

Small Molecule to Inhibit Kappa Opioid Receptor for CNS-Drug Profile 210

Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders-Drug Profile 211

Small Molecules to Agonize Alpha 4 Neuronal Nicotinic Receptor for Smoking Cessation-Drug Profile 212

Small Molecules to Agonize NOP for Pain and Alcohol Addiction-Drug Profile 213

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction-Drug Profile 214

Small Molecules to Inhibit DAT and SERT for CNS Disorders-Drug Profile 215

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 216

Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation-Drug Profile 217

Small Molecules to Inhibit NTR1 for Psychiatric Disorders-Drug Profile 218

Small Molecules to Modulate 5HT2 for CNS and Metabolic Disorders-Drug Profile 219

sodium oxybate IR-Drug Profile 220

Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction-Drug Profile 221

Synthetic Peptides to Target DOR, MOR and MRP-1 for Oncology and CNS Disorders-Drug Profile 222

TA-CD-Drug Profile 223

TKM-ALDH2-Drug Profile 224

TV-1380-Drug Profile 225

Vaccine for Cocaine Addiction-Drug Profile 226

Vaccine for Cocaine Addiction-Drug Profile 227

Vaccine for Methamphetamine Addiction-Drug Profile 228

Vaccine for Nicotine Addiction-Drug Profile 229

Vaccine for Nicotine Addiction-Drug Profile 230

Vaccine for Opium Addiction-Drug Profile 231

VMD-2202-Drug Profile 232

Addiction-Recent Pipeline Updates 233

Addiction-Dormant Projects 261

Addiction-Discontinued Products 268

Addiction-Product Development Milestones 270

Featured News & Press Releases 270

Appendix 278

Methodology 278

Coverage 278

Secondary Research 278

Primary Research 278

Expert Panel Validation 278

Contact Us 278

Disclaimer 279

List of Tables

Number of Products under Development for Addiction, H1 2015 20

Number of Products under Development for Addiction-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 23

Number of Products under Development by Companies, H1 2015 (Contd..1) 24

Number of Products under Development by Companies, H1 2015 (Contd..2) 25

Number of Products under Development by Companies, H1 2015 (Contd..3) 26

Number of Products under Development by Companies, H1 2015 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 30

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Development, H1 2015 32

Comparative Analysis by Unknown Stage Development, H1 2015 33

Products under Development by Companies, H1 2015 34

Products under Development by Companies, H1 2015 (Contd..1) 35

Products under Development by Companies, H1 2015 (Contd..2) 36

Products under Development by Companies, H1 2015 (Contd..3) 37

Products under Development by Companies, H1 2015 (Contd..4) 38

Products under Development by Companies, H1 2015 (Contd..5) 39

Products under Development by Companies, H1 2015 (Contd..6) 40

Products under Investigation by Universities/Institutes, H1 2015 41

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 42

Addiction-Pipeline by AbbVie Inc., H1 2015 43

Addiction-Pipeline by Acura Pharmaceuticals, Inc., H1 2015 44

Addiction-Pipeline by Addex Therapeutics Ltd, H1 2015 45

Addiction-Pipeline by Adial Pharmaceuticals, LLC, H1 2015 46

Addiction-Pipeline by Alkermes Plc, H1 2015 47

Addiction-Pipeline by Aphios Corporation, H1 2015 48

Addiction-Pipeline by Aradigm Corporation, H1 2015 49

Addiction-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 50

Addiction-Pipeline by Astraea Therapeutics, LLC, H1 2015 51

Addiction-Pipeline by AstraZeneca PLC, H1 2015 52

Addiction-Pipeline by Beech Tree Labs, Inc., H1 2015 53

Addiction-Pipeline by BioDelivery Sciences International, Inc., H1 2015 54

Addiction-Pipeline by Bionex Pharmaceuticals LLC, H1 2015 55

Addiction-Pipeline by Bioprojet SCR, H1 2015 56

Addiction-Pipeline by Camurus AB, H1 2015 57

Addiction-Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015 58

Addiction-Pipeline by Cerecor Inc., H1 2015 59

Addiction-Pipeline by Curemark, LLC, H1 2015 60

Addiction-Pipeline by D&A Pharma SAS, H1 2015 61

Addiction-Pipeline by Eli Lilly and Company, H1 2015 62

Addiction-Pipeline by Embera NeuroTherapeutics, Inc., H1 2015 63

Addiction-Pipeline by Euthymics Bioscience, Inc., H1 2015 64

Addiction-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 65

Addiction-Pipeline by FORUM Pharmaceuticals Inc., H1 2015 66

Addiction-Pipeline by Gilead Sciences, Inc., H1 2015 67

Addiction-Pipeline by GlaxoSmithKline plc, H1 2015 68

Addiction-Pipeline by Grunenthal GmbH, H1 2015 69

Addiction-Pipeline by Heptares Therapeutics Ltd., H1 2015 70

Addiction-Pipeline by Immunovaccine, Inc., H1 2015 71

Addiction-Pipeline by Indivior PLC, H1 2015 72

Addiction-Pipeline by INSYS Therapeutics, Inc., H1 2015 73

Addiction-Pipeline by Invion Limited, H1 2015 74

Addiction-Pipeline by Johnson & Johnson, H1 2015 75

Addiction-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 76

Addiction-Pipeline by Lightlake Therapeutics Inc., H1 2015 77

Addiction-Pipeline by Lohocla Research Corporation, H1 2015 78

Addiction-Pipeline by MAKScientific, LLC, H1 2015 79

Addiction-Pipeline by NAL Pharmaceuticals Ltd., H1 2015 80

Addiction-Pipeline by Nanotherapeutics, Inc., H1 2015 81

Addiction-Pipeline by Omeros Corporation, H1 2015 82

Addiction-Pipeline by Pfizer Inc., H1 2015 83

Addiction-Pipeline by Relmada Therapeutics, Inc., H1 2015 84

Addiction-Pipeline by Rottapharm SpA, H1 2015 85

Addiction-Pipeline by Royalty Pharma, H1 2015 86

Addiction-Pipeline by Selecta Biosciences, Inc., H1 2015 87

Addiction-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 88

Addiction-Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 89

Addiction-Pipeline by Targacept, Inc., H1 2015 90

Addiction-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 91

Addiction-Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 92

Addiction-Pipeline by Titan Pharmaceuticals, Inc., H1 2015 93

Addiction-Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2015 94

Addiction-Pipeline by VM Discovery, Inc., H1 2015 95

Addiction-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 96

Assessment by Monotherapy Products, H1 2015 97

Assessment by Combination Products, H1 2015 98

Number of Products by Stage and Target, H1 2015 100

Number of Products by Stage and Mechanism of Action, H1 2015 103

Number of Products by Stage and Route of Administration, H1 2015 106

Number of Products by Stage and Molecule Type, H1 2015 108

Addiction Therapeutics-Recent Pipeline Updates, H1 2015 241

Addiction-Dormant Projects, H1 2015 269

Addiction-Dormant Projects (Contd..1), H1 2015 270

Addiction-Dormant Projects (Contd..2), H1 2015 271

Addiction-Dormant Projects (Contd..3), H1 2015 272

Addiction-Dormant Projects (Contd..4), H1 2015 273

Addiction-Dormant Projects (Contd..5), H1 2015 274

Addiction-Dormant Projects (Contd..6), H1 2015 275

Addiction-Discontinued Products, H1 2015 276

Addiction-Discontinued Products (Contd..1), H1 2015 277

List of Figures

Number of Products under Development for Addiction, H1 2015 20

Number of Products under Development for Addiction-Comparative Analysis, H1 2015 21

Number of Products under Development by Companies, H1 2015 22

Number of Products under Investigation by Universities/Institutes, H1 2015 28

Comparative Analysis by Clinical Stage Development, H1 2015 31

Comparative Analysis by Early Stage Products, H1 2015 32

Assessment by Monotherapy Products, H1 2015 97

Assessment by Combination Products, H1 2015 98

Number of Products by Top 10 Targets, H1 2015 99

Number of Products by Stage and Top 10 Targets, H1 2015 99

Number of Products by Top 10 Mechanism of Actions, H1 2015 102

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 102

Number of Products by Top 10 Routes of Administration, H1 2015 105

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 106

Number of Products by Top 10 Molecule Types, H1 2015 107

Number of Products by Stage and Top 10 Molecule Types, H1 2015 108

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Acura Pharmaceuticals, Inc.

Addex Therapeutics Ltd

Adial Pharmaceuticals, LLC

Alkermes Plc

Aphios Corporation

Aradigm Corporation

Arena Pharmaceuticals, Inc.

Astraea Therapeutics, LLC

AstraZeneca PLC

Beech Tree Labs, Inc.

BioDelivery Sciences International, Inc.

Bionex Pharmaceuticals LLC

Bioprojet SCR

Camurus AB

Celtic Pharmaceutical Holdings L.P.

Cerecor Inc.

Curemark, LLC

D&A Pharma SAS

Eli Lilly and Company

Embera NeuroTherapeutics, Inc.

Euthymics Bioscience, Inc.

Foresee Pharmaceuticals, LLC

FORUM Pharmaceuticals Inc.

Gilead Sciences, Inc.

GlaxoSmithKline plc

Grunenthal GmbH

Heptares Therapeutics Ltd.

Immunovaccine, Inc.

Indivior PLC

INSYS Therapeutics, Inc.

Invion Limited

Johnson & Johnson

Kyorin Pharmaceutical Co., Ltd.

Lightlake Therapeutics Inc.

Lohocla Research Corporation

MAKScientific, LLC

NAL Pharmaceuticals Ltd.

Nanotherapeutics, Inc.

Omeros Corporation

Pfizer Inc.

Relmada Therapeutics, Inc.

Rottapharm SpA

Royalty Pharma

Selecta Biosciences, Inc.

SK Biopharmaceuticals Co., Ltd.

Sun Pharma Advanced Research Company Ltd.

Targacept, Inc.

Tekmira Pharmaceuticals Corp.

Teva Pharmaceutical Industries Limited

Titan Pharmaceuticals, Inc.

Tonix Pharmaceuticals Holding Corp.

VM Discovery, Inc.

Zynerba Pharmaceuticals, Inc.

Addiction Therapeutic Products under Development, Key Players in Addiction Therapeutics, Addiction Pipeline Overview, Addiction Pipeline, Addiction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com